Promising results for use of catabolic enzyme inhibitors in treatment of PTSD
The US National Institute on Alcohol Abuse’s AM-3506 and Sanofi’s SAR-411298 are both at the preclinical stage of development for PTSD.
Trends in clinical trials for gene therapies in neurology
84% of gene therapy trials happening in various neurology indications, listed in GlobalData’s Pharma Intelligence Center, are in early-stage development, that is Phase I, Phase I/II, and Phase II.
Psilocybin depression therapy faces cost-effectiveness challenges versus J&J’s Spravato
Companies researching psilocybin therapy have ongoing Phase II or III clinical trials, but will need to optimise the treatment paradigm to streamline costs, experts said.
Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis
Nuplazid is being investigated for the treatment of delusions and hallucinations associated with dementia-related psychosis (DRP).
Promising results for the use of catabolic enzyme inhibitors in post-traumatic stress disorder
The pipeline for PTSD includes several therapies intended to be administered alongside psychotherapy to maximise positive outcomes for patients with common comorbidities such as anxiety and depression.
Straight to the source – targeted pain relief
Diamyd Medical, a Swedish biopharmaceutical company, has taken huge steps towards revolutionising the treatment of intractable pain. Through their Nerve Targeting Drug Delivery System (NTDDS) the developers hope to bring new relief to cancer, diabetes and chronic pain sufferers. Dr Nicola Davies reports.
Snapshot: The market for neuropathic pain therapeutics
As conditions such as diabetes become more common, the market for new pain drugs is becoming increasingly competitive. Using detailed GlobalData research this snapshot examines the market forces behind a sector expected to grow by 9.6% from $4.8bn in 2010 to $10bn in 2018.
Preventing the Fallout: Anti-Radiation Drugs
The disaster at the Fukushima nuclear plant in Japan has triggered demand for a powerful anti-radiation drug. Elisabeth Fischer finds out what options are currently out there and asks just how prepared are countries in the face of a nuclear fallout?